Giant Cell Tumors are a group of tumors that contain giant cells. The most common types are Giant Cell Tumor of Bone and Giant Cell Tumor of Tendon Sheath.
Every report comes from a Lived member, sent anonymously.
Have you had Curettage for Giant Cell Tumors?
Giant cell tumors are a group of tumors named for the unusually large cells, each formed from several cells fused together, that are seen under the microscope. The name covers two main conditions that behave differently. Giant cell tumor of bone grows inside a bone, usually at the end of a long bone next to a joint, and most often around the knee. Tenosynovial giant cell tumor (TGCT) grows in the thin lining of a joint (the synovium) or in the sleeve that surrounds a tendon (the tendon sheath). Both are usually noncancerous, but they can be locally aggressive, meaning they grow into and damage nearby bone, cartilage or tendon. That is what causes the pain, swelling and stiffness, and it is why treatment usually aims to remove the tumor before it harms the joint. TGCT comes in two forms. The localized form is a single nodule, often on a finger, hand or wrist, and usually responds well to surgery. The diffuse form, once called pigmented villonodular synovitis (PVNS), spreads through much of a joint lining, most often the knee, and is harder to treat. Giant cell tumor of bone can weaken the bone enough to break it. In rare cases it spreads to the lungs while still being benign, and very rarely it is a true cancer.
The cause of giant cell tumor of bone is not known. It develops on its own, is not linked to injury, diet or environmental exposures, and is not inherited. It is rare, affecting about 1 person in a million each year. Most cases appear between ages 20 and 40, after the skeleton has finished growing, and it is slightly more common in women. In TGCT, the tumor cells carry a genetic change that makes them overproduce a signaling protein called colony-stimulating factor 1 (CSF1). CSF1 draws large numbers of inflammatory cells into the joint lining or tendon sheath, and that buildup produces the swelling and pain. This is also why newer medicines that block the CSF1 signal can shrink the tumor. No environmental exposure or other health condition is known to raise the risk. TGCT occurs most often between ages 20 and 50 and is more common in women. Neither tumor is caused by anything a person did, and there is no known way to prevent them.
Diagnosis starts with an examination of the painful or swollen area and imaging. For giant cell tumor of bone, an X-ray usually shows an area near the joint where the bone looks eaten away, sometimes with the bone slightly expanded around it. A magnetic resonance imaging (MRI) scan shows whether the tumor has broken through the bone into surrounding tissue, and a chest X-ray or CT scan checks whether it has reached the lungs. A biopsy, in which a small sample is taken with a needle or a minor operation and examined under a microscope, is usually needed to confirm the diagnosis, because the tumor can look aggressive on scans and has to be told apart from other bone tumors. For TGCT, there is no blood test. X-rays may look normal unless the bone is already affected. MRI is the most useful test: it shows the nodule or thickened joint lining, how far it extends, any damage to cartilage and bone, and signs of old bleeding inside the joint that point toward this tumor. If fluid is drawn from a swollen joint, it is often bloody even without a significant injury. Many cases can be diagnosed from the symptoms and MRI, with a biopsy when the picture is unclear. Because TGCT symptoms can come and go and resemble more common joint problems, many people have symptoms for years before the diagnosis is made.
Without treatment, giant cell tumor of bone keeps growing and destroying bone, so it is treated rather than watched. Surgery is the most effective option. Most often the surgeon scrapes the tumor out of the bone (curettage), treats the cavity with something such as liquid nitrogen or hydrogen peroxide to kill remaining tumor cells, and fills it with bone cement or bone graft to restore strength. This usually preserves the joint. If the tumor has badly damaged the bone or joint, the affected section may be removed and rebuilt with bone graft, a joint replacement or both. If the tumor has spread to the lungs, those spots can often be removed surgically, or watched closely if they are small. When surgery is not possible or would cause serious disability, denosumab (Xgeva), an injection that blocks the signal the giant cells use to break down bone, can stop the destruction and shrink the tumor. It does not eliminate the underlying tumor cells, so the tumor grows back when treatment stops, and using it to shrink a tumor before surgery may raise the chance of recurrence afterward. Treatment involves calcium and vitamin D supplements, blood calcium checks and a dental exam before starting, because it can lower calcium and, rarely, damage the jawbone. In people with this tumor, calcium can also rise too high in the weeks to months after stopping, so it is checked after the last dose too. Radiation is reserved for rare situations, such as tumors in the spine, because it can cause a new cancer years later. For TGCT, a tumor that causes no symptoms can sometimes be watched with regular exams and MRI. Otherwise, surgery removes the tumor and the affected lining. A localized nodule is usually removed whole, with tendon repair if needed. Diffuse disease in a joint may be removed through small incisions with a camera (arthroscopy), which is easier to recover from but more likely to leave tumor behind, or through open surgery, which removes the lining more completely at the cost of a bigger operation and more risk of stiffness. A badly damaged joint may need replacement. Radiation is sometimes used for diffuse disease that keeps returning, but evidence is limited and it can cause stiffness, joint damage and a later cancer. For adults whose TGCT causes real symptoms and where surgery would likely worsen function, two pills that block the CSF1 signal are approved: vimseltinib (Romvimza) and pexidartinib (Turalio). In the placebo-controlled trial behind vimseltinib's approval, 40% of people had meaningful tumor shrinkage after about six months, compared with none on placebo, and joint range of motion improved. Its common side effects include swelling around the eyes, tiredness and rash. Both medicines require regular liver blood tests. Pexidartinib can cause serious, sometimes fatal liver injury and is available only through a restricted safety program, while vimseltinib has mostly caused raised liver enzymes, abnormal blood test results that the regular liver tests are meant to catch. Denosumab, vimseltinib and pexidartinib can all harm a developing baby, so effective contraception is needed during treatment and for a time after the last dose. Pexidartinib can stop hormonal birth control from working, so a non-hormonal method is needed with it.
These tumors are rarely life-threatening, but they can take a lasting toll on a joint, and coming back after treatment is the main long-term concern. That is why follow-up continues well after the tumor is removed. After treatment for giant cell tumor of bone, check-ups usually continue for several years, with X-rays of the treated site and chest X-rays or CT scans to watch the lungs. Results depend on the person's age, the tumor's size and location, and the kind of surgery. Someone who stays on denosumab needs ongoing visits, because the tumor tends to return once the medicine stops. For TGCT, the outlook depends heavily on the form. Localized tumors are reported to return in about 10 to 30% of people within five years, and diffuse tumors in about 20 to 70%. Physical therapy is an important part of recovery. After arthroscopic surgery, a short course is usually enough before returning to normal activity. After open surgery for diffuse disease, getting back to all usual activities can take several months, and stiffness is more likely. Diffuse disease inside a joint can leave long-term stiffness, pain and arthritis, and some people benefit from help from a pain specialist. After treatment for diffuse TGCT, an MRI every 6 to 12 months for several years is common. People taking a CSF1-blocking medicine have regular liver tests and periodic scans to judge whether it is working.
Arrange an appointment for a lump that is growing, or for pain, swelling, stiffness, locking or catching in a joint that persists or keeps getting worse, especially pain near a joint that increases with activity. Repeated swelling of a joint without a clear injury also deserves evaluation. If you have already been treated, tell your care team about new pain, swelling or a lump at the treated site rather than waiting for the next scheduled scan. If you have giant cell tumor of bone and develop sudden, severe pain at the tumor site, or suddenly cannot bear weight on or use the limb, get seen the same day, because the weakened bone may have broken.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Giant Cell Tumors is like, what's helped you, or ask the community a question.